论文部分内容阅读
自五十年代初至今,糖皮质激素(Glucocorticoid, GC)用于治疗哮喘已近40年,学者们对GC在治疗哮喘中的地位尚存在不同的看法。目前国内多数医师在治疗哮喘时,如用支气管扩张剂能控制症状则往往不用GC,而国外某些学者将GC作为治疗哮喘的第一线药物并主张早期使用,而支气管扩张剂则为对症辅助治疗剂。本文根据1986年seplsepcr会议期间举行《类固醇治疗哮喘理论与临床研讨会报告》的资料,扼要介绍当今各国哮喘研究者对GC的治疗作用机理与其在治疗
Since the early 1950s, Glucocorticoid (GC) has been used to treat asthma for nearly 40 years. Scholars have different views on the status of GC in the treatment of asthma. At present, most physicians in the treatment of asthma, such as the use of bronchodilators can often control the symptoms are not GC, and some foreign scholars will GC as the first line of treatment of asthma drugs and advocate early use, and bronchodilators are symptomatic aid Therapeutic agents. Based on the data from the “Report on the Theory and Clinical Symposium on Steroid Treatment of Asthma” held during the seplsepcr conference in 1986, this article briefly introduced the current therapeutic mechanisms of GC treatment by asthma researchers in various countries and their clinical significance